Skip to Main Content
Diabetes Mellitus - Type 1, Phase I

TrialNet TOPPLE Study for People with Type 1 Diabetes

What is the purpose of this trial?

TrialNet is testing the safety of a new treatment, NNC0361-0041, in adults, 18-45, with Type 1 Diabetes (T1D) diagnosed within the past 48 months. The treatment is a plasmid vector designed to transfer DNA into cells, where it can communicate with the immune system. Earlier studies in the lab show this treatment might retrain the immune system to stop its attack on insulin-producing beta cells.

While plasmids are small circular pieces of DNA, they do not change your DNA. They are currently being studied in many clinical trials for other conditions.

This study has a 12-week treatment phase, followed by 9 months of follow up.

  • Trial with
    National Institute of Diabetes and Digestive & Kidney Diseases (NIDDK)
  • Ages
    18 years - 45 years
  • Gender

Contact Information

For more information about this study, including how to volunteer, contact Lori Carria

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact, or call 877.978.8343 for more information.

  • Last Updated
  • Study HIC